France, Germany and Portugal announce resumption of AstraZeneca vaccine


Germany, France and Portugal announced that they should resume the application of the covid-19 vaccine developed by the AstraZeneca, in partnership with Oxford University. Several European countries have suspended the use of the vaccine after recording possible serious cases of blood clots forming in people who received a dose of the immunizer. Last Tuesday, however, the European Medicines Agency (EMA, in the acronym in English) announced that there was no evidence that the use of the vaccine influenced the reactions.

“In clinical trials, both vaccinated people and those who received placebo showed no changes in the evaluation of clotting data. And the number of clot formation events among vaccinees also does not appear to be greater than that observed in the general population” , said EMA Executive Director Emer Cooke.